secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2025-04-21T23:59:59+00:00
Accession:  0001837607-25-000030
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma appoints Robert Bancroft as CEO effective April 29; Jost Fisher remains chairman
--------------------------------------------------------------------------------

- Bancroft appointed PEO, President, CEO and Class I director effective April 29, 2025.
- Jost Fisher steps down as Interim CEO but continues as chairman and on audit/comp committees.
- Bancroft base salary $425k, eligible for annual bonus target 50% of salary.
- Bancroft receives 59,034 stock options and 177,103 RSUs under new Inducement Plan (1M shares reserved).
- Prior role: GM of Therapeutics at Revance Therapeutics until its acquisition by Crown Labs in Feb 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000183760725000030/0001837607-25-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000183760725000030/aeon-20250419x8k.htm
  HTML page:      https://secwatch.observer/filing/0001837607-25-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer